“COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN RESECTED EGFR-MUTATED EARLY-STAGE NON-SMALL CELL LUNG CANCER IN THAILAND”. Proceedings of the International Conference on Public Health 9, no. 1 (January 23, 2025): 45–67. Accessed October 14, 2025. https://www.proceedings.tiikmpublishing.com/index.php/icoph/article/view/1543.